(lp0
S"Celgene Corporation's  Management Presents at Barclays Global Healthcare ... Seeking Alpha - Mar 15, 2017 Okay, welcome to the second day of the Barclays Global Healthcare Conference. My name is Geoff Meacham. I'm the Senior Biopharma Analyst."
p1
aS'Celgene: In Breakout Mode? Seeking Alpha - Mar 16, 2017 Biotech stalwart Celgene touched $140 in the early summer of 2015 just before a bear market swept over the biotech sector. With sentiment on this area of the market improving and this biotech juggernaut continuing to execute, shares touched a one year&nbsp;...'
p2
aS"Celgene: A Growth Stock You Don't Want To Miss Seeking Alpha - Mar 10, 2017 The company operates in more than 60 countries and sells its products in more than 70. In 2016, Celgene generated sales of $11.2 billion."
p3
aS"Celgene Corporation Posted losses of -2.13% in the Last Trade Free Observer - 15 hours ago Currently the shares of Celgene Corporation  has a trading volume of 4.42 Million shares, with an average trading volume of 4.02 Million shares - with shares dropping to a 52 week low of $94.42 on Jun 27, 2016, and the company's shares&nbsp;..."
p4
aS"Analysts Keeping an Eye on: Celgene Corporation  Post Registrar - 16 hours ago Celgene Corporation  plunged -2.13% during previous trade, a total of 4.37M shares exchanged hands compared with its average trading volume of 3.98M shares whereas its relative volume is 1.08.Updated Trading Report: Celgene Corporation  - Is storiesWhat are Analyst's Indicators for Celgene Corporation , Mylan NV  - The USA Commerce"
p5
aS"Celgene: A 'Fuggedaboutit' Core Biotech Holding Seeking Alpha - Feb 23, 2017 Few large-cap biotech concerns have a clearer earnings and revenue growth trajectory over the next 3-5 years than Celgene. It has a blockbuster blood cancer drug, several other solid compounds in its product portfolio, a deep pipeline, and dozens of&nbsp;..."
p6
aS'Celgene Clarifies Matters At The Cowen Conference; Takeaways Seeking Alpha - Mar 10, 2017 The main questions have been the prospects to replace Revlimid sales next decade, and whether ozanimod for MS could be a blockbuster.Celgene Co.  Downgraded by Zacks Investment Research to Hold - Sports Perspectives'
p7
aS'Celgene Corporation  Stock Is Staging a Tempting Breakout Investorplace.com - Mar 10, 2017 If there was ever a doubt, the latest price action in Celgene Corporation  should help ease those fears and usher in more investor cheer in the coming weeks.'
p8
aS"Celgene Announces Oral OTEZLA Demonstrated Significant Improvement vs Placebo ... Benzinga - Mar 5, 2017 Celgene Corporation  today announced that results from its phase 4 UNVEIL trial evaluating OTEZLA , the Company's oral, selective inhibitor of phosphodiesterase 4 , in patients with moderate plaque psoriasis with a&nbsp;..."
p9
aS'An intrinsic value calculation for Celgene Corporation  shows investors ... Simply Wall St - Mar 6, 2017 Does the March share price for Celgene  reflect its intrinsic value? I am going to calculate it now using a method called discounted cash flow or DCF.'
p10
a.